CDIO
NASDAQCardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings Inc. (CDIO) is a Biotechnology: In Vitro & In Vivo Diagnostic Substances company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for CDIO, including 1 SEC filing. The most recent was published Nov 6, 2026.
Financial highlights
Full financials- Revenue, TTM
- $15.2K
- Revenue growth
- -3.8%
- Net income, TTM
- -$6.49M
- Net margin
- -42721.9%
- Free cash flow, TTM
- -$5.78M
- Cash
- $0
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks22-75%
2026-05-172026-11-08
Mix1090d
- SEC Filings4(40%)
- Insider4(40%)
- Other2(20%)
Activity · 52 weeks3823 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by Cardio Diagnostics Holdings Inc.10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
- INSIDERSEC Form 4 filed by Director Betts Wendy J4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
- INSIDERSEC Form 4 filed by Director Fung Peter K4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
- INSIDERSEC Form 4 filed by Director Intrater James4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
- INSIDERSEC Form 4 filed by Director Burton Paul Frederick4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
- SECCardio Diagnostics Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
- SECSEC Form DEFA14A filed by Cardio Diagnostics Holdings Inc.DEFA14A - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
- PRCardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access ChallengesThe report reflects the current state of rural cardiovascular care in America and offers an exclusive roadmap for rural health organizations navigating ongoing workforce shortages and access challenges.Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the release of a new edition of the company’s rural health report, "The State of Rural Hospitals and Cardiovascular Care," aimed at helping rural healthcare leaders, policymakers, and community-based organizations improve cardiovascular care quality and outcomes in rural areas.Ongoing Workforce Shortages and Access ChallengesThe rural healthcare workforce shortage is signifi
- SECCardio Diagnostics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
- PRCardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa CityThe new in-house laboratory facility will give Cardio Diagnostics end-to-end ownership of test processing and expand research capabilities for ongoing and future studies in precision monitoring of cardiovascular health. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the official launch of its in-house, high complexity CLIA-certified laboratory in Iowa City, Iowa. The new facility gives Cardio Diagnostics end-to-end control over the processing of its multi-omics clinical tests, Epi+Gen CHD™ and PrecisionCHD™, from sample receipt to result delivery, replacing the third-party arrangement previously used for clinical sa
- SECSEC Form 10-Q filed by Cardio Diagnostics Holdings Inc.10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
- SECSEC Form DEFA14A filed by Cardio Diagnostics Holdings Inc.DEFA14A - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
- SECSEC Form DEF 14A filed by Cardio Diagnostics Holdings Inc.DEF 14A - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
- PRCardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Thursday, August 20, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company’s precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, ongoing and planned studies, reimbursement progress, and strategic growth initiatives. Webcast and
- SECSEC Form PRE 14A filed by Cardio Diagnostics Holdings Inc.PRE 14A - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
- INSIDERSEC Form 4 filed by Director Fung Peter K4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
- INSIDERSEC Form 4 filed by Director Betts Wendy J4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
- INSIDERSEC Form 4 filed by Director Intrater James4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
- INSIDERSEC Form 4 filed by Director Burton Paul Frederick4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
- PRAtlas Healthcare Physicians to Cover Cardio Diagnostics’ Precision Cardiovascular Medicine Tests Across Its NetworkCardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians (AHP), a community-driven, independent physician association (IPA) based in Southern California, will cover Cardio Diagnostics’ tests, Epi+Gen CHD™ and PrecisionCHD™, for their members with prior authorization beginning May 2026. AHP consists of an expansive network of primary care and specialists, hospitals, and ancillary providers serving managed care populations across Los Angeles and Orange County. Providers will recommend Epi+Gen CHD™ or PrecisionCHD™ based on a patient’s medical history. Epi+Gen CHD™ assesses the three-year risk of a co
- PRCardio Diagnostics Holdings, Inc. to Showcase Precision Cardiovascular Solutions at Four National Benefits Conferences in JuneThese evidence-based solutions help employers, brokers, and unions tackle cardiovascular disease, a leading driver of medical claims and lost productivity. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced that the company will exhibit at four upcoming national benefits conferences, connecting with employers, brokers, union trustees, and plan administrators on a shared challenge: cardiovascular disease (CVD). CVD remains a leading medical claims cost driver for most health plans and a major contributor to absenteeism, disability, and lost workforce productivity. Cardio Diagnostics' clinically validated blood tests,
- PRIBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Meesha Dogan, CEO of Cardio Diagnostics Holdings Inc.AUSTIN, Texas, May 20, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Meesha Dogan, CEO and Co-Founder of Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), a precision cardiovascular medicine company leveraging epigenetics, genetics,
- SECSEC Form 10-Q filed by Cardio Diagnostics Holdings Inc.10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
- PRIBN Initiates Coverage of Cardio Diagnostics Holdings Inc.AUSTIN, Texas, April 08, 2026 (GLOBE NEWSWIRE) -- via IBN -- Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, has engaged IBN, a multifaceted financial news and publishing company serving private and public entities, to assist with its corporate communications strategy. Cardio Diagnostics develops and commercializes blood-based clinical tests and data solutions designed to support the prevention, detection, and management of cardiovascular disease. Its approach integrates epigenetic and genetic biomarkers with artificial intel
- INSIDERSEC Form 4 filed by Fung Peter K4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
CDIO FAQ
9 questionsWhat is the latest news on CDIO?
In the last 30 days Quantisnow tracked 1 wire item for CDIO: 1 SEC filing. The most recent was published on November 6, 2026.What is CDIO revenue?
Cardio Diagnostics Holdings Inc. (CDIO) reported $15.2K of revenue for the twelve months ended Sep 30, 2026. That is down 3.8% from the year before. Revenue for fiscal 2025 was $14.8K.Is CDIO profitable?
No. Cardio Diagnostics Holdings Inc. reported a net loss of $6.49M for the twelve months ended Sep 30, 2026.How much cash and debt does CDIO have?
Cardio Diagnostics Holdings Inc. reported $0 in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does CDIO stock trade?
Cardio Diagnostics Holdings Inc. (CDIO) is listed on NASDAQ.What sector and industry is CDIO in?
Cardio Diagnostics Holdings Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did Cardio Diagnostics Holdings Inc. go public?
Cardio Diagnostics Holdings Inc. (CDIO) completed its IPO in 2022.What companies are similar to CDIO?
Notable peers in the same industry include LNTH (Lantheus Holdings Inc.), ORKA (Oruka Therapeutics Inc.), ACHV (Achieve Life Sciences Inc.), NTLA (Intellia Therapeutics Inc.), CLDX (Celldex Therapeutics Inc.). Compare CDIO side-by-side with any of them on Quantisnow.How can I track CDIO on Quantisnow?
Quantisnow aggregates Cardio Diagnostics Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CDIO to receive live email and push alerts on every new disclosure.